Home / Healthcare / Teriflunomide - Key patent, SPC, and data exclusivity expiry (44 country coverage)

Teriflunomide - Key patent, SPC, and data exclusivity expiry (44 country coverage)

Published: Mar 2015 | Published By: GenericsWeb
Pipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players.
 
This Pipeline Selector report covers Teriflunomide
 
  • Teriflunomide indications: Treatment of relapsing multiple sclerosis
  • Teriflunomide innovator: Sanofi (Aubagio); Genzyme (Aubagio)
 
Examples of information found in this online report include:
 
  • Includes key patent publications for 44 countries (see list below)
  • Contains SPC protection for every EU state plus patent term extensions in other countries
  • Data exclusivity calculated on a country by country basis
  • Summary of dosage forms, strengths, indications and active ingredient forms of the brand product
  • DMF & Paragraph IV filings
  • Litigation alerts
  • Marketing authorisation holders in selected territories
  • Patent risk analysis via graphical display of data from patent filings
  • Hyper-linking to crucial patent documents and national registries enabling data verification
 
The 'Key Patent Indicator' enables easy identification of key patent, SPC and data protection expiry information covering 44 countries, including extension details (SPC and national law) for 30 European countries, Australia, Israel, Japan and the USA. (also available with 44 country coverage):
 
Pipeline Selector 44 Country Coverage:
 
  • Country Region Extensions
  • Australia Asia-Pacific S70
  • Canada Americas N/A
  • USA Americas S156
  • Germany Western Europe SPC
  • Great Britain Western Europe SPCS
  • France Western Europe NAT/SPC
  • Spain Western Europe SPC
  • South Africa Africa N/A
  • China Asia-Pacific N/A
  • Japan Asia-Pacific S67
  • New Zealand Asia-Pacific N/A
  • Bosnia & Herzegovina Balkan N/A
  • Bulgaria Balkan SPC
  • Croatia Balkan N/A
  • Romania Balkan SPC
  • Slovenia Balkan NAT/SPC
  • Estonia Baltic NAT/SPC
  • Lithuania Baltic NAT/SPC
  • Latvia Baltic NAT/SPC
  • Czech Republic Central Europe NAT/SPC
  • Hungary Central Europe SPC
  • Poland Central Europe SPC
  • Slovakia Central Europe NAT/SPC
  • Serbia & Montenegro Central Europe N/A
  • Cyprus Mediterranean NAT/SPC
  • Greece Mediterranean SPC
  • Israel Mediterranean NAT
  • Malta Mediterranean SPC
  • Turkey Mediterranean N/A
  • Denmark Scandinavia SPC
  • Finland Scandinavia SPC
  • Iceland Scandinavia SPC
  • Norway Scandinavia SPC
  • Sweden Scandinavia SPC
  • Brazil South America N/A
  • Mexico South America N/A
  • Austria Western Europe SPC
  • Belgium Western Europe SPC
  • Switzerland Western Europe NAT/SPC
  • Ireland Western Europe SPC
  • Italy Western Europe NAT/SPC
  • Luxembourg Western Europe SPC
  • The Netherlands Western Europe SPC
  • Portugal Western Europe SPC
 
Other key information contained in the report:
 
  • Summary of dosage forms, strengths, indications and active ingredient forms of the brand product in major countries**. 
  • News articles
  • Litigation alerts
  • Marketing authorisation holders for Great Britain, the United States, Canada and Australia enable you to see who is active in the market.
  • US Drug Master Files, providing valuable information to help source active ingredients and keep an eye on competitors.
  • Paragraph IV filing; details of US ANDAs filed with a Paragraph IV certification allow easy determination of who the first movers are for a particular generic product in the US.
  • 'Patent Risk Analysis' section containing three graphical displays of data drawn from known patent filings to provide valuable competitor insight and development information***.
 
*Key Patent Indicator
 
The 'Key Patent Indicator' section is intended only to provide an indication of the Key Patents pertaining to a generic drug, and is not based on a comprehensive patent search (a comprehensive patent search can be found in the corresponding Pipeline Selector report). 
 
**General Drug Information
 
Information contained in 'General Indications' and 'Brand Product Attributes' is based on products containing the active pharmaceutical ingredient, which are currently registered in Australia, UK and the USA. Indications are summarised where appropriate and may vary between individual countries.
 
***Patent Risk Analysis
 
The three graphical analyses are based on data contained in our Pipeline Selector comprehensive patent search, and thus are subject to its scope and limitations. These graphics are intended to provide only a summary of the patent filings; specific details of the filings should be investigated through the use of the Pipeline Selector reports.
 
Pipeline Selector is just one of the benchmark products from GenericsWeb's Pipeline Patent Intelligence product suite.

Pipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players.

  • Includes key patent publications for 44 countries 
  • Contains SPC protection for every EU state plus patent term extensions in other countries
  • Data exclusivity calculated on a country by country basis
  • Summary of dosage forms, strengths, indications and active ingredient forms of the brand product
  • DMF & Paragraph IV filings
  • Litigation alerts
  • Marketing authorisation holders in selected territories
  • Patent risk analysis via graphical display of data from patent filings
  • Hyper-linking to crucial patent documents and national registries enabling data verification
Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +